We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Australian prescription medicine decision summaries
Search our decision summaries for the registration of new prescription medicines.
For more information, visit the About Australian prescription medicine decision summaries information page.
We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia.
The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Search
226 result(s) found, displaying 126 to 150
-
Prescription medicine decision summaryTGA decision: Rholistiq (belumosudil mesilate) is approved to treat chronic graft-versus-host disease (GVHD)
-
Prescription medicine decision summaryTGA decision: Illuccix (Glu-urea-Lys(ahx)-hbed-CC) is a radioactive diagnostic agent used to assist in the treatment of prostate cancer.
-
Prescription medicine decision summaryTGA decision: Truseltiq (infigratinib) is approved to treat cholangiocarcinoma.
-
Prescription medicine decision summaryTGA decision: Bevacip/Bevaciptin (bevacizumab) is approved to treat various types of cancers.
-
Prescription medicine decision summaryTGA decision: VeraSeal (human fibrinogen/ human thrombin) is approved to treat hemostasis.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Prescription medicine decision summaryAustralian prescription medicine decision summary